ReviewDrug design, development and therapy2018

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.

Silvia Paola Corona et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.